CYTK 49.75 ▼ -0.48% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Cytokinetics

    NASDAQ: CYTK · Real-Time Price · USD
    49.75
    -0.24 (-0.48%)
    At close: Sep 04, 2025, 3:59 PM
    50.88
    2.27%
    Pre-market: Sep 05, 2025, 06:20 AM EDT
    -0.48%
    Bid 48
    Market Cap 5.95B
    Revenue (ttm) 85.74M
    Net Income (ttm) -606.31M
    EPS (ttm) -5.12
    PE Ratio (ttm) -9.72
    Forward PE -8.86
    Analyst Buy
    Ask 51.69
    Volume 2,945,069
    Avg. Volume (20D) 1,731,158
    Open 50.30
    Previous Close 49.99
    Day's Range 48.93 - 51.69
    52-Week Range 29.31 - 59.39
    Beta 0.65

    About CYTK

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CYTK
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for CYTK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Cytokinetics is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 days ago
    +40.45%
    Cytokinetics shares are trading higher after the c... Unlock content with Pro Subscription
    4 months ago
    -12.98%
    Cytokinetics shares are trading lower after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.

    2 days ago · youtube.com

    Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

    Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

    news image

    2 days ago · zacks.com

    Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

    CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.

    news image

    3 days ago · seekingalpha.com

    Cytokinetics, Incorporated (CYTK) Presents At Citi's Biopharma Back To School Conference Transcript

    Cytokinetics, Incorporated (NASDAQ:CYTK ) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Robert I. Blum - CEO, President & Director Fady Malik - Executiv...

    news image

    3 days ago · seekingalpha.com

    Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential

    MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is signif...

    news image

    3 days ago · seekingalpha.com

    Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript

    Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of...

    news image

    3 days ago · barrons.com

    Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.

    Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.

    news image

    6 days ago · reuters.com

    Cytokinetics' drug more effective for heart disease symptoms than standard-of-care

    Cytokinetics' experimental drug improved symptoms such as shortness of breath and chest pain better than a standard-of-care treatment in patients with a type of heart condition, detailed late-stage st...

    news image

    6 days ago · investors.com

    Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease

    Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

    news image

    2 weeks ago · seekingalpha.com

    Cytokinetics: Specialty Franchise With Aficamten And Ulacamten

    CYTK's Aficamten is easily their main value driver. It has an oHCM PDUFA for December 26, 2025. Aficamten's late-cycle FDA meeting is in September. Plus, it has a potential future as a monotherapy, pe...

    news image

    4 weeks ago · seekingalpha.com

    Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call Transcript

    Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants & - Corporate Participant Andrew M. Callos - Executive VP & Chief Commercial O...

    Add to Watchlist